Company intelligence / Profile preview

Parithera SA

Epalinges, Vaud, Switzerlandparithera.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Parithera has developed an integrated solution combining CTC enrichment and sample preparation for sequencing within a single device. Their technology enables minimally invasive, accurate guidance on cancer treatment decisions by analyzing circulating tumor cells from blood. The company’s approach aims to help clinicians monitor response and adapt therapies based on real-time molecular information. Clinical validation efforts are ongoing.[1][3]

Therapeutic areas: Oncology
Modalities: Liquid biopsy (single-cell analysis)Circulating Tumor Cells (CTCs) enrichment and sequencing preparationAI-driven data analysisSingle-cell RNA sequencing
Industry: Molecular Diagnostics

Partnerships

Seeking partnerships with ADC, bispecific & CAR-T developers [1].

Beyond the preview

Go deeper on Parithera SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parithera SA.

Explore the full profile